MOTS-c is a 16-amino-acid peptide produced by mitochondrial DNA that activates AMPK and mimics some of the metabolic effects of exercise. It was discovered in 2015 at USC, and animal studies show it improves insulin sensitivity, reduces fat mass, and reverses age-related physical decline. Human data is still very limited, which makes the "exercise in a bottle" nickname both partially accurate and significantly premature. MOTS-c works at the mitochondrial level; see our Mitochondrial Health Peptides: SS-31 MOTS-c and Humanin Guide for 2026 guide.
Key Takeaway
MOTS-c is a mitochondrial-derived peptide that activates the same AMPK pathway triggered by exercise. Mouse studies are promising, showing improved metabolism, reduced obesity, and better physical function with aging. But no completed human clinical trials have tested exogenous MOTS-c administration, and calling it "exercise in a bottle" overstates the current evidence. Another metabolic peptide is covered in our AOD-9604 peptide complete guide.
What Is MOTS-c and How Was It Discovered?
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c. It is a peptide encoded by mitochondrial DNA, specifically within the MT-RNR1 gene. This is unusual. Most biologically active peptides are encoded by nuclear DNA. The fact that mitochondria produce their own signaling peptides was a relatively new concept when MOTS-c was discovered.
The discovery came from Changhan David Lee's lab at the USC Leonard Davis School of Gerontology. Lee and his team published the initial characterization in Cell Metabolism in March 2015 (PMID: 25738459). They identified MOTS-c as a circulating peptide that, when injected into mice, prevented diet-induced obesity and improved insulin sensitivity. The finding opened up a new category of biological signaling: mitochondria communicating with the rest of the cell (and the rest of the body) through encoded peptides.
MOTS-c is not the only mitochondrial-derived peptide. Humanin, discovered earlier, is another. But MOTS-c received more attention because its effects so closely resembled exercise, which immediately sparked interest in longevity and metabolic health research. MOTS-c is a key component in the The Ultimate Longevity Peptide Stack for Maximum Healthspan.
How Does MOTS-c Work at the Cellular Level?
The primary mechanism of MOTS-c involves AMPK activation. AMPK (AMP-activated protein kinase) is the cell's master energy sensor. When cellular energy is low (during exercise, fasting, or metabolic stress), AMPK activates pathways that increase glucose uptake, promote fat oxidation, improve mitochondrial function, and suppress inflammation.
MOTS-c activates AMPK through an indirect route. It inhibits the folate cycle and de novo purine biosynthesis in cells, which creates a state of metabolic stress that triggers AMPK. This is mechanistically different from how exercise activates AMPK (through AMP/ATP ratio changes), but the downstream effects overlap considerably.
A 2018 study from Lee's lab showed that MOTS-c does something even more unexpected: it translocates from the mitochondria to the nucleus during metabolic stress, where it directly regulates nuclear gene expression. This was the first time a mitochondrial-encoded peptide was shown to enter the nucleus and influence gene transcription (PMC6185997). The genes it regulates are involved in glucose metabolism, antioxidant defense, and proteostasis (protein quality control).
More recently, researchers identified casein kinase 2 (CK2) as a direct molecular target of MOTS-c, providing a more specific understanding of how the peptide modulates skeletal muscle function at the protein level.
What Did the Animal Studies Show?
The animal data on MOTS-c is consistent and positive across multiple studies:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Obesity prevention (2015). The original Cell Metabolism paper showed that MOTS-c treatment prevented high-fat-diet-induced obesity in mice and improved insulin resistance. Mice treated with MOTS-c gained less fat mass and had better glucose tolerance than untreated controls (PMID: 25738459).
Age-related decline (2021). A study published in Nature Communications found that MOTS-c treatment improved physical performance in young (2 months), middle-aged (12 months), and old (22 months) mice. Treated mice ran further and maintained better muscle homeostasis. The study also confirmed that exercise increases endogenous MOTS-c production in both mice and humans (PMID: 33473109).
Diabetes models (2025). Recent research demonstrated that MOTS-c restored mitochondrial respiration in type 2 diabetic heart tissue and lowered fasting blood glucose in diabetic rat models. These findings extend the metabolic benefits of MOTS-c beyond skeletal muscle to cardiac tissue.
| Study | Year | Model | Key Finding |
|---|---|---|---|
| Lee et al., Cell Metabolism | 2015 | Mice (high-fat diet) | Prevented obesity, improved insulin sensitivity via AMPK |
| Kim et al., Cell Metabolism | 2018 | Mice (metabolic stress) | MOTS-c translocates to nucleus, regulates gene expression |
| Reynolds et al., Nature Comms | 2021 | Mice (aging) + human tissue | Improved physical performance in old mice; exercise induces MOTS-c in humans |
| Frontiers in Physiology | 2025 | Rats (type 2 diabetes) | Restored mitochondrial respiration in diabetic heart tissue |
What Do We Know About MOTS-c in Humans?
The human data is limited but interesting. No completed clinical trial has tested exogenous MOTS-c injections in humans. What we know comes from observational and exercise-based studies:
The 2021 Nature Communications study included a human exercise component. Researchers collected skeletal muscle and plasma from healthy young men who exercised on a stationary bicycle. MOTS-c levels in muscle tissue increased nearly 12-fold during exercise. Plasma MOTS-c levels rose by about 50% during and after exercise, then returned to baseline after a 4-hour rest period (PMID: 33473109).
This confirms that humans produce MOTS-c naturally and that exercise triggers its release. It also raises the question: is MOTS-c one of the mechanisms by which exercise produces its metabolic benefits? If so, supplementing with exogenous MOTS-c could theoretically replicate some of those benefits. But "could theoretically" and "does in practice" are separated by clinical trials that have not yet been completed.
Observational studies have found that circulating MOTS-c levels are lower in older adults and in people with type 2 diabetes, suggesting the peptide may be a biomarker for metabolic health. People with higher natural MOTS-c levels tend to have better insulin sensitivity and lower body fat. But correlation is not causation, and it is possible that healthier people simply produce more MOTS-c as a byproduct of better metabolic function.
Is "Exercise in a Bottle" an Accurate Description?
Partially. MOTS-c activates AMPK, which is the same pathway activated by exercise. It improves insulin sensitivity, promotes fat oxidation, and supports mitochondrial function, all of which are exercise effects. In old mice, it improved physical performance to a degree that is hard to achieve through other interventions.
But exercise does far more than activate AMPK. A single bout of exercise triggers hundreds of molecular cascades involving myokines, cardiovascular adaptation, neuroplasticity, bone remodeling, immune modulation, and psychological effects. No single peptide can replicate the full spectrum of exercise benefits. MOTS-c mimics the metabolic component, not the structural, cardiovascular, or neurological components.
A more accurate description would be "metabolic exercise mimetic." It captures one important dimension of exercise's effects without pretending to replace exercise entirely. Anyone using MOTS-c should still exercise. The peptide, if its effects translate to humans, would be an adjunct to physical activity, not a replacement for it.
What Are the Typical Research Doses Discussed Online?
Online peptide communities discuss MOTS-c at doses typically ranging from 5-10mg injected subcutaneously, 2-3 times per week. Some protocols use daily dosing at 5mg. These doses are extrapolated from mouse studies and anecdotal human use. No human clinical trial has established an optimal dose, a safety profile, or a dosing schedule.
Because MOTS-c is a peptide, it must be injected. Oral administration would result in digestion before the peptide reaches systemic circulation. The subcutaneous route is standard for research peptides of this type.
It is worth noting that the MOTS-c available from research peptide suppliers has not been evaluated by the FDA for human use. Purity, potency, and sterility vary between suppliers. This is a common issue with research peptides and represents a real risk for anyone using them outside of a clinical trial. For more on the world of research peptides, see our peptide therapy guide. New to peptides? Start with our Peptide Therapy: Complete Guide to Benefits, Types, and Safety [2026]. MOTS-c regulatory status is covered in our FDA peptide ban overview.
What Is the Current Research Status of MOTS-c?
As of early 2026, MOTS-c remains in the preclinical and early translational research phase. The key developments:
- The original 2015 discovery paper has been cited over 700 times, indicating broad scientific interest.
- The 2021 Nature Communications aging study strengthened the case for MOTS-c as an exercise mimetic and anti-aging peptide.
- 2025 studies on diabetic cardiac tissue expanded the potential therapeutic applications beyond obesity and aging.
- The identification of CK2 as a direct target provided the first mechanistic explanation beyond AMPK activation.
- No FDA-approved clinical trial of exogenous MOTS-c in humans has been completed.
The gap between animal evidence and human application is significant. Many peptides with strong mouse data fail to translate to humans. The physiological differences between species, including metabolism rate, peptide clearance, and immune response, mean that positive mouse results are necessary but not sufficient for predicting human efficacy.
MOTS-c is a genuinely interesting molecule with a solid mechanistic basis and consistent animal data. Whether it will live up to its "exercise in a bottle" reputation in human studies remains to be determined. The science is promising. The hype is ahead of the evidence.
Frequently Asked Questions
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for any indication. It is a research peptide. Any MOTS-c available for purchase is sold for research purposes only and has not been evaluated for safety or efficacy in humans by any regulatory agency.
Can MOTS-c replace exercise?
No. MOTS-c mimics some metabolic effects of exercise (AMPK activation, improved insulin sensitivity) but does not replicate the cardiovascular, musculoskeletal, neurological, or psychological benefits of physical activity. Even if MOTS-c proves effective in humans, it would be a supplement to exercise, not a substitute.
Who discovered MOTS-c?
Changhan David Lee, PhD, and his team at the USC Leonard Davis School of Gerontology first characterized MOTS-c in a 2015 paper published in Cell Metabolism. Lee continues to lead MOTS-c research and has published follow-up studies on its role in aging and exercise.
Does your body produce MOTS-c naturally?
Yes. MOTS-c is an endogenous peptide produced by mitochondria. Exercise increases MOTS-c production, with muscle levels rising nearly 12-fold during exercise in one study. Levels tend to decline with age, which is one reason researchers are interested in exogenous supplementation.
What is AMPK and why does it matter?
AMPK (AMP-activated protein kinase) is the cell's energy sensor. When activated, it promotes glucose uptake, fat burning, mitochondrial biogenesis, and autophagy. Exercise, fasting, and metformin all activate AMPK. MOTS-c activates AMPK through a different pathway (folate cycle inhibition) but produces overlapping metabolic effects.
Are there side effects of MOTS-c?
No human safety data exists from controlled clinical trials. Mouse studies have not reported significant adverse effects, but mice and humans metabolize peptides differently. Without human trials, the side effect profile of exogenous MOTS-c administration is unknown.
How is MOTS-c different from other exercise-mimicking compounds like GW501516?
GW501516 (Cardarine) is a synthetic PPAR-delta agonist with documented carcinogenic risk in animal studies. MOTS-c is an endogenous peptide your body already produces. The safety profiles are very different. MOTS-c mimics a natural signal; GW501516 is a pharmaceutical compound with known toxicity concerns at research doses.
Medical References
- Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109
- Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524. PMC6185997
- Zhai D, et al. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol. 2017;92:151-160. PMID: 29100110
- Yin X, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025;16:1602271. DOI: 10.3389/fphys.2025.1602271
- Kang GM, et al. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes Metab J. 2023;47(3):315-326. DOI: 10.4093/dmj.2023.0016
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any medication or protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10